Alterity医疗 ATHE 深 沪
等待开盘 02-06 09:30:00 美东时间
3.19
+0.055
+1.75%
华盛通- 最 高3.3199
- 今 开3.20
- 成交量 2.89万股
- 最 低 3.19
- 昨 收 3.135
- 总市值 5782.10万
- 52周最高 7.00
- 市盈率 静 --
- 换手率 0.16%
- 52周最低 2.5209
- 委 比 99.61%
- 总股本 1812.57万
- 历史最高 51.50
- 量 比 3.11
- 振 幅 4.14%
- 历史最低 1.001
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics provided an update on its activities for Q2 FY26, highlighting advancements in its MSA program, Phase 2 data strengthening, and planning for a pivotal Phase 3 trial. The company presented additional analyses of the Phase 2 trial at international congresses, including improved efficacy signals for ATH434 at the 75 mg dose. Regulatory planning for an End-of-Phase 2 meeting with the FDA in mid-2026 is progressing, with a focus ...
01-30 12:25
Alterity Targets $2.4B Market as Lead Drug Clears Phase 2 and Moves Toward Phase 3
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to
01-21 20:27
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
Alterity Therapeutics (ATH) achieved Phase 2 success for ATH434 in treating Multiple System Atrophy (MSA), demonstrating safety, efficacy, and disease progression slowing. Results position the company for Phase 3 planning and potential entry into a $2.4B market. Key 2026 milestones include FDA-end-of-Phase 2 meeting, expanding engagement, and scaling infrastructure. The company also strengthened its leadership team to support growth. Alterity rem...
01-21 12:25
Alterity Flags Risk Context for Forward-Looking Statements in 2026 Presentation
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
01-13 08:18
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
Alterity Therapeutics Announces Director Departure
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
2025-11-24 11:28
Alterity Therapeutics CEO Outlines Strategic Vision
Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeut...
2025-11-21 09:07
Alterity Therapeutics Advances in Neurodegenerative Disease Treatment
Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics...
2025-11-21 08:57
Alterity Therapeutics Announces Board Restructuring for Growth
An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alte...
2025-11-21 07:28
Alterity Therapeutics Discloses Equity Derivative Positions
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
2025-11-13 12:48
